Overview
RCUS market data
Price History
RCUS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.82 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.84 – $31.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $3.4K · P/B 4.67 · P/S 14.46.
Company News
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026Benzinga · Jul 22, 2026, 8:48 PM
Arcus Biosciences And Summit Therapeutics Announced A Clinical Trial Collaboration To Evaluate The Safety And Efficacy Of Arcus’s Casdatifan; Data Expected to Be Generated By Mid-2027Benzinga · Jul 22, 2026, 8:34 PM
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?Benzinga · Jul 20, 2026, 6:45 PM
Arcus Biosciences shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $32 to $45.Benzinga · Jul 20, 2026, 2:35 PM
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45Benzinga · Jul 20, 2026, 10:55 AM
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% RunThe Motley Fool · Jul 14, 2026, 11:00 AM
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney CancerBenzinga · Jul 1, 2026, 3:10 PM
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35Benzinga · May 18, 2026, 3:10 PM
8-K filing — Arcus Biosciences, Inc. (RCUS)SEC EDGAR · May 5, 2026, 8:09 PM